# CLL14 (NCT02242942)

> Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02242942
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Lymphocytic Leukemia, Chronic
- Interventions: Chlorambucil; Venetoclax; Obinutuzumab
- Enrollment: 445
- Primary outcome: Progression Free Survival (PFS) Based on Investigator Assessment According to IWCLL Criteria

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

Discussion covers CLL14’s fixed-duration venetoclax-obinutuzumab regimen, comparator and long-term follow-up, including subgroup patterns involving IGHV, TP53, disease bulk and MRD, alongside quality-of-life measures. Speakers discuss treatment selection between time-limited therapy and continuous BTK inhibition, including the optimal approach for unmutated IGHV or high-risk disease. Questions include whether MRD should guide treatment duration and whether therapy should continue when MRD remains detectable. Commentary also raises control-arm crossover and access, and venetoclax ramp-up monitoring in renal impairment or bulky disease.

## Indexed commentary on CLL14 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 119
- Podcasts: 77
- X threads: 33
- X videos: 3
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cll14-nct02242942

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02242942", "email": "<work email>"}; the inbox owner confirms by the emailed link.